RAD51's pan‐cancer disease‐specific survival (DSS) analysis predicted poor prognosis in nine cancers: OSCC, MESO, LGG, KIRP, LUAD, pancreatic adenocarcinoma (PAAD), HNSC, skin cutaneous melanoma (SKCM) and BLCA, with statistical significance (p < 0.05). Here, RAD51 is linked to cancer.